Skip to Main Content

Insights

forest trees covered by fog that looks similar to a lung

July 23, 2024

How Cos. Should Handle Research Org.'s Carcinogen Evals

By John Kalas, Joseph E. Fornadel, III, Matthew Abney

Law360

In an article published in Law360 on July 22, Nelson Mullins partners John Kalas, Joe Fornadel, and associate Matthew Abney discussed the International Agency for Research on Cancer’s (IARC) recent priority list for evaluation and how to proactively create a legal strategy.

“IARC’s upcoming evaluations have the potential to affect currently pending litigation and may stimulate new or renewed litigation regarding products and exposures not currently subject to mass torts,” they explained. “By virtue of its association with the United Nations and because of the participation of many individuals associated with impressive institutions, the IARC Working Group classifications may be held in high regard by jurors and/or members of the general public. Formulating a litigation strategy before IARC meets is key to being prepared after the meeting results are released.”

 To read the full article, subscribers may click here.